Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by Craigbadon Nov 18, 2016 12:26pm

223 Views

Post# 25481487

RE:RE:RE:RE:RE:More colour on this very positive acquisition

Looks like a debt to ebitda well up in the danger zone. Almost looks like a Concordia in the making. Might make for an interesting short position. Will check with a few friends, only concern is the lack of volume.

digitel wrote: Add the debt to the market cap and divide by EBTDA an what's MPH worth?

$60 million in debt.
$8 million in run-rate EBITDA for MPH based upon the last quarter.
US$3.5 million in EBITDA for Apicore in 2015 and MPH now controls 60%.
$60 million in debt at 9.5% interest.
One million warrants adding to MPH's fully diluted share count.